David Guyer is the Chairman of the Board of Directors of Tenpoint Therapeutics. He brings expansive medical, drug development, and commercial experience in ophthalmology. David co-founded EyeBio with Anthony P.Adamis, M.D., in August 2021. Today he holds the title of EyeBio Co-founder,President, and Chief Executive Officer (CEO). David is also a Venture Partner at SV Health Investors and is Co-Founder and former CEO and Executive Chairman of Iveric Bio (previously Ophthotech). David served as Chairman of Iveric Bio’s board of directors from 2007 to 2017, as CEO from 2013 to 2017, and asExecutive Chairman from 2017 to 2021. Under his leadership, Iveric Bio entered into a partnership with Novartis that, at the time, was one of the largestex-U.S. partnering transactions in biotechnology industry history.
David has served on the boards of approximately 20companies, both public and private. In addition to co-founding EyeBio andIveric Bio, David co-founded Eyetech Pharmaceuticals Inc. and served as its CEO and member of the board of directors from 2000 until the company’s acquisition by OSI Pharmaceuticals, Inc. in November 2005. He developed the firstanti-VEGF agent for AMD while at Eyetech. Prior to co-founding Eyetech Pharmaceuticals, David was a professor and Chairman of the Department of Ophthalmology at New York University School of Medicine.
David received a BS from Yale College and an MD from Johns Hopkins Medical School. He completed his ophthalmology residency atWilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
